May require funding but ultimately very positive.
• Bloomberg's M&A team have reported that AZN may be about to sign $15bn licensing deal with Summit.
• It could include "several billion dollar upfront" payment. The rest in milestone payments.
• The deal would give AZN access to Summit's ivonescimab drug for lung cancer.
• Ivonescimab inhibits blood vessel formation in tumours using antibodies.
• This is a direct competitor to Keytruda which generates $31bn per year for Merck.
Find more articles and bullets on these widgets:
"The United Kingdom Debt Management Office (DMO) announces that the new index-linked gilt, which will mature on 22 September 2038, will pay a coupon of 1 3/4% per annum, payable semi-annually. The new gilt will have the ISIN code GB00BMY62Z61 and the SEDOL code B-MY6-2Z6 and will pay a short first coupon on 22 September 2025."
The JOLTS report for April was on balance one of relative stability in another look at early reaction to Trump administration policies. Job openings surprisingly increased whilst the hire rate pushed to its highest since September although the quits rate pushed back lower again after what to us was a surprising uptick back in March. Of course, this is only for April in a fast-moving environment.
